Bhupendra Rawal, MSBiostatistician III
Bhupendra Rawal is a statistician at the Department of Biostatistics and Computational Biology at Dana-Farber Cancer Institute. His areas of research and collaboration include the design and implementation of phase I / II / III clinical trials, observational & retrospective studies, survival & competing risk analysis, and longitudinal mixed models. He has been interested and involved in the cancer-immunotherapy vaccine & CAR T cell research. As an applied statistician, Bhup collaborates with the clinicians and researchers from multiple-myeloma, cancer-immunotherapy, and radiation oncology.


Department of Biostatistics and Computational Biology 
Dana-Farber Cancer Institute 
450 Longwood Avenue
Boston MA  02215

2007 - MS, Biostatistics, University of Massachusetts, Amherst, MA

2005 - MS, Mathematics, Southern Illinois University, Carbondale, IL

1992 - M.Sc, Mathematics, Tribhuvan University, Kathmandu, Nepal

1988 - B. Sc, Math / Phy / Chem, Kumaun University, Nainital, India



Link to all publications: Google Scholar

  1. Mihalcik SA., Rawal B., Braunstein LZ., Capuco A., Wong JS., Punglia RS., Bellon JR., Harris JR. “The Impact of Reexcision and Residual Disease on Local Recurrence Following Breast-Conserving Therapy”. Ann Surg Oncol. 2017 Jan 30. PMID: 28138856.
  1. Danielle N. Margalit, Bhupendra Rawal, Paul J Catalano,  Robert I Haddad, Laura A Goguen, Donald J Annino, Sewanti A Limaye,  Jochen H Lorch,  Annie W Lavigne, Jonathan D Schoenfeld,  David J Sher, Roy B Tishler “Patterns of Failure after Reirradiation with Intensity-Modulated Radiation Therapy and the Competing Risk of Out-of-Field Recurrences” Oral Oncology, Oct 2016, PMID: 27688100.
  1. Ram A. Pathak, Bhupendra Rawal, Zhuo Li, Gregory A. Broderick “Novel, Evidence-Based, Classification of Cavernous Venous Occlusive Disease (CVOD)”. Journal of Urology, May 2016, PMID: 27164516.

  1. Sanjay P. Bagaria, Nabil Wasif, Bhupendra Rawal, Sarah A. McLaughlin, Armando E. Giuliano “Is mastectomy undertreatment for low risk breast cancers eligible for breast -conserving therapy?” Cancer, Apr 2015; PMID: 25920382.

  1. Eric Haura, Tawee Tanvetyanon, Alberto Chiappori, Charles Williams, George Simon, Scott Antonia, Jhanelle Gray, Sharon Litshauer, Leticia Tettia, Anthony Neuger, Lanxi Song, Bhupendra Rawal, Michael J. Schell, and Gerold Bepler “Phase I/II Study of SRC Inhibitor Dasatinib in Combination with Erlotinib in Advanced Non-Small- Cell Lung Cancer”. Journal of Clinical Oncology 2010 Feb PMID: 20142592